Collaboration designed to assess key molecular targets associated for phase I clinical trial
[ANN ARBOR, MI and PHOENIX, AZ, August 19, 2015] Paradigm today announced a pharmaceutical services relationship with Deciphera Pharmaceuticals for a phase I clinical study of Altiratinib in molecularly defined cancers driven by either MET or TRK genomic alterations including lung cancer, gastric cancer, renal cancer, and glioblastoma multiforme (GBM).
Paradigm will use its Paradigm Cancer Diagnostic (PCDx) panel’s advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to Deciphera’s Altiratinib, a MET/TIE2/VEGFR2/TRK (A,B,C) kinase inhibitor, which has been granted an Orphan Drug Designation for GBM by the FDA. PCDX is also broadly available to assist cancer patients and their oncologists find actionable FDA approved therapies.
Robert J. Penny MD, PhD, CEO of Paradigm noted “Paradigm is successfully working with leading biopharmaceutical companies to craft personalized interrogations for clinical trial selection and is providing accelerated translational treatment decisions in patient care as part of our PCDx panel.”
# # #
Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit http://www.paradigmdx.com.